
|Articles|August 1, 2003
Higher Dosing 'Difficult to Straddle'
Author(s)Andrew Bowser
Chicago - Escalating doses of an antibody to CTLA-4 in conjunction with a peptide vaccine showed the induction of antigen-specific immune responses and potential evidence of autoimmunity in patients with stage III/IV resected melanoma, according to Jeffrey M. Weber, M.D., Ph.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
4
"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions
5


















